Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-i... Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients. Show more
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -1.80995475113 | 2.21 | 2.32 | 2.05 | 16990 | 2.16120582 | CS |
4 | -1.16 | -34.8348348348 | 3.33 | 3.7032 | 2.05 | 49593 | 2.86060674 | CS |
12 | -2.55 | -54.0254237288 | 4.72 | 5 | 2.05 | 24335 | 3.27014321 | CS |
26 | -2.43 | -52.8260869565 | 4.6 | 5.59 | 2.05 | 16321 | 3.6734525 | CS |
52 | -0.96 | -30.6709265176 | 3.13 | 6.46 | 2.05 | 17324 | 4.21924173 | CS |
156 | -44.45 | -95.3453453453 | 46.62 | 47.5993 | 2.05 | 108027 | 12.30740936 | CS |
260 | -32.0131 | -93.6518338009 | 34.1831 | 133.7 | 2.05 | 385288 | 54.29831266 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales